ArticleOncology reviews2023

Rationale for the Use of Homologous Recombination Proficient Molecular Profile as a Biomarker for Therapeutic Targeting in Ovarian Cancer.

John Nemunaitis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.